Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | GPR17 | Q13304 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2922043 | 0.85 | LMNA (0.46) | FFAR1FFAR4FOLH1LMNANPSR1 | |
| SCHEMBL27037031 | 0.81 | FFAR1 (0.50) | FFAR1FFAR4KEAP1GPR17NPSR1 | |
| SCHEMBL29010055 | 0.81 | FFAR1 (0.39) | FFAR1FFAR4KEAP1GPR17NPSR1 | |
| SCHEMBL8491907 | 0.81 | CNR1 (0.34) | FOLH1 | |
| SCHEMBL22129230 | 0.81 | POLB (0.40) | FFAR1FFAR4GPR17NPSR1 | |
| SCHEMBL30572278 | 0.79 | CAPN1 (0.38) | LMNA | |
| SCHEMBL10752209 | 0.77 | ALDH1A1 (0.43) | LMNA | |
| SCHEMBL5266797 | 0.77 | TET2 (0.31) | FOLH1 | |
| SCHEMBL18519306 | 0.75 | HTT (0.35) | — | |
| SCHEMBL4717038 | 0.75 | FFAR1 (0.49) | FFAR1FFAR4KEAP1GPR17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1498978-B1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND LITHIUM SECONDARY BATTERY EMPLOYING THE SAME | UBE INDUSTRIES (JP) | 2010-09-08 | — | — | EP | claimed |
| EP-0553107-B1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | PROCYON PHARM INC (US) | 1999-09-29 | — | — | EP | claimed |
| US-20250361249-A1 | SURFACE TREATMENT AGENT | DAIKIN INDUSTRIES, LTD. (JP) | 2025-11-27 | — | — | US | disclosed |
| EP-4644398-A1 | SURFACE TREATMENT AGENT | Daikin Industries, Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| WO-2024172036-A1 | SURFACE TREATMENT AGENT | ダイキン工業株式会社 | 2024-08-22 | — | — | WO | disclosed |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | NURA BIO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2024-04-11 | — | — | US | disclosed |
| CN-111032669-B | Orthoester compositions for affinity purification of oligonucleotides | 安捷伦科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | NURA BIO, INC. | 2023-10-26 | — | — | US | disclosed |
| US-5891870-A | ANTIINFLAMMATORY AGENTS USING BENZODITERPENES AND BENZOLACTAMS | PROCYON PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5891906-A | Polyacetate-derived phorboids having anti-inflammatory and other uses | PROCYON PHARMACEUTICALS, INC. (US) | 1999-04-06 | — | — | US | disclosed |
| US-5886019-A | REPLACEMENT OF HYDROXYMETHYL OR-ETHYL GROUP ON TRICYCLIC AROMATIC HETEROCYCLIC COMPOUNDS HAVING INDOLE, INDENE, BENZOFURAN OR BENZOTHIOPHENE SKELETON; ANTIINFLAMMATORY, ANTIVIRAL | PROCYON PHARMACEUTICALS, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| US-5750568-A | DITERPENE PHORBOIDS | PROCYON PHARMACEUTICALS, INC. (US) | 1998-05-12 | — | — | US | disclosed |
| US-5716968-A | ANTIINFLAMMATORY AGENTS; VIRICIDE | PROCYON PHARMACEUTICALS, INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5643948-A | ANTIINFLAMMATORY, ANTICANCER | PROCYON PHARMACEUTICALS, INC. (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0614360-A1 | SUBSTITUTED -g(b)-AMINO ACID DERIVATIVES USEFUL AS PLATELET AGGREGATION INHIBITORS. | SEARLE & CO (US) | 1994-09-14 | — | — | EP | disclosed |
| EP-0553107-A1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | PROCYON PHARMACEUTICALS, INC. (US) | 1993-08-04 | — | — | EP | disclosed |
| WO-1992002484-A1 | PROTEIN KINASE C MODULATORS WITH ANTI-INFLAMMATORY AND ANTIVIRAL ACTIVITY | ALDER RESEARCH CENTER LIMITED PARTNERSHIP (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404265-B2 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885KEAP1 534/4885 |
| US-11970481-B1 | Substituted pyridine derivatives as SARM1 inhibitors | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885KEAP1 534/4885 |
| US-20230339913-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885KEAP1 534/4885 |
| US-20240116901-A1 | SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS | SARM1, SARNP, ADRM1 | FFAR1 4246/4885FFAR4 4580/4885KEAP1 534/4885 |
| US-20250361249-A1 | SURFACE TREATMENT AGENT | ITGA1, ITGB1, GDI1 | FFAR1 43/4885FFAR4 832/4885KEAP1 2665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.